Favorable effects on metabolic risk factors with daily brewer's yeast in type 2 diabetic patients with hypercholesterolemia: A semi-experimental study

Background: The aim of the present study was to investigate the effect of brewer's yeast on plasma glucose and lipid profiles in patients with type 2 diabetes (T2D). Methods: The present semi-experimental study was performed on 55 T2D patients with hypercholesterolemia. All patients received 12 tablets of 300 mg yeast per day for 8 weeks. Each tablet contained 1.2 mu g chromium. Fasting plasma glucose, total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), and triglyceride levels were measured at baseline and then again at Weeks 4 and 8. Results: Although there was a tendency for plasma glucose levels to decrease at Week 4, the difference failed to reach statistical significance (P = 0.065). However, after 8 weeks, the decrease in plasma glucose was significant (P = 0.043). Again, although there was a tendency for decreased plasma cholesterol at Week 8 compared with baseline, the difference failed to reach statistical significance (215 +/- 29 vs 226 +/- 37 mg/dL, respectively; P = 0.056). Brewer's yeast significantly decreased plasma triglyceride and LDL-C levels at Weeks 4 and 8. In contrast, plasma HDL-C levels were significantly increased at both 4 and 8 weeks compared with baseline (41.3 perpendicular to 8.8 and 43.3 perpendicular to 7.5 vs 36 perpendicular to 5 mg/dL, respectively; P < 0.01 and P < 0.01, respectively). Conclusion: In conclusion, the consumption of brewer's yeast over a period of 8 weeks may improve cardiometabolic risk factors in T2D patients. However, these findings need to be confirmed in a large double-blind clinical trial.